Sepehr Shojaei serves as the vice president of design solutions at Lightship, using his 15 years of experience in clinical research operations to champion a patient-centric approach.
An online portal enabling people worldwide to find and express interest in clinical trials has been launched by Clinical Trial Media, a clinical trial participant recruitment and retention company.
AION Labs, the first-of-its-kind venture studio today (January 8) announced its new partnership with Amiti Ventures, a leading early-stage venture capital firm in Israel.
A £30 million ($38 million) study into liver cirrhosis, the most extensive ever conducted worldwide has been announced by Newcastle University and University of Edinburgh, funded by Boehringer Ingelheim.
There is an urgent and unmet need to better understand the features of acute respiratory distress syndrome (ARDS), which is why a clinical research business has been selected to start a phase 2 platform clinical trial to investigate it further.
The pharmaceutical industry in 2023 has seen many investments, partnerships, acquisitions and more. As the year ends, industry leaders give the biggest trends to look for in 2024, with artificial intelligence being a hot topic.
The AIDS and Cancer Specimen (ACSR), a biorepository of specimens collected from persons living with HIV (PLWH) has today (December 12) announced it is using software from Proscia that can provide near real-time access to pathology data to investigators...
Clinical-stage pharma company, PharmaKure which develops precision medicine for Alzheimer’s Disease and other neurological diseases has announced a collaboration agreement with one of the largest comprehensive universities in Malaysia.
The first six companies enter the Deep Tech Lab - Quantum start-up accelerator at BioInnovation Institute (BII) to unlock the potential in quantum science
Outsourcing Pharma is delighted to invite you to join our not-to-be-missed webinar on one of the most important areas of the industry – patient centricity – and its solutions.
Volunteers with conditions including depression, alcohol use disorder, and anorexia are being sought by Clerkenwell Health, to join its seminal clinical trials.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced last week (November 23) the submission of a type 2 extension of indication application to the European Medicines Agency (EMA).
OSP was delighted to speak to Galina Nesterova, executive medical director at the Rare Disease & Pediatrics Center of Excellence, and Susan McCune, vice president of pediatrics and clinical pharmacology both within medical science and strategy at...
Vice president and global head of bioanalytical and central lab services, Lan Li has always found doctors fascinating. Their ability to save lives and give second chances set her on her career path, but it was recognizing there were still so many unmet...
Unfortunately, more than 700 rare diseases affect more than 30 million people in the US alone and with many of them being life threatening, it is still a concern that most still do not have treatments.
Clinical stage pharma company PharmaKure believe their combined drug targeting amyloid deposits associated with Alzheimer’s Disease can bring quality of life to patients.
The treatment of rare brain disease, progressive supranuclear palsy (PSP), that has no disease modifying therapies, has been given a glimmer of hope by Amylyx Pharmaceuticals.
A collaboration has been formed between the US pharmacy chain Walgreens and the Cardiovascular Research Foundation (CRF) to measure how prevalent valvular heart disease (VHD) is among older Americans.
Physics-powered GenAI Biotech, Gero, announced yesterday (October 18) that it had closed a $6 million series A extension round with funding from Melnicheck Investments and other investors.
The heavy burden on immediate family members with neurodegenerative diseases and their caregivers, was the initial driving force to study pharmacy for Andrea Pfeifer.
A new patient-first service that will support sponsors and sites accelerate the development of their therapies has been launched by Innovative Trials yesterday (October 9).
Former UK Prime Minister, David Cameron, will lead the international efforts of The Oxford-Harrington Rare Disease Centre's new initiative, the therapeutics accelerator.
A new approach to discovering targets for Alzheimer’s and other neurodegenerative diseases has been presented by Insilico Medicine with the University of Cambridge, UK.
At-risk families of patients diagnosed with motor neurone disease (MND), better known in the US as amyotrophic lateral sclerosis (ALS) will now have access to genetic sequencing thanks to a financial award from Innovate UK.
Updated guidelines for risk-based quality management (RBQM) are much more than just for monitoring purposes and can show quality by design concepts, save immeasurable time on manpower and shows there has been a complete mindset shift within the last 15...
Positive phase 3 results from a trial studying fruquintinib, in patients with previously treated colorectal cancer (CRC) were announced by Hutchmed and Takeda on Friday (June 16).
Slope, a site-first organization, ‘eliminating the chaos’ impacting clinical trials has joined CancerX as a founding member of The White House’s national Cancer Moonshot.
Artificial intelligence (AI) biotech company, Owkin, has invested $50million in a project that will use spatial omics, a set of cutting-edge technologies that offer unprecedented information on the structure of tumors.
Research has reinforced the efficacy of Lumakras (sotorasib), a small molecule inhibitor in advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC).
A London-based start-up that says clinical trials are ‘the biggest bottleneck to improving human health’ is launching a number of ‘breakthrough’ treatments for conditions including tinnitus, insomnia and progressive childhood short-sightedness.
A company developing small molecule therapeutics targeting DNA Damage Response (DDR) in order to treat patients with a broad range of cancers has its first assay development customer.
H1, a US data healthcare data technology company has been selected by non-profit funder of Parkinson’s Disease (PD) research, The Michael J Fox Foundation (MJFF), for its Trial Landscape solution.
The UK has the tools to become a life-sciences superpower but those thinking about taking part remain put off by the lack of financial motivation, a clinical trials start-up says.